Cresset Asset Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $13.2M | Sell |
61,258
-6,245
| -9% | -$1.19M | 0.05% | 233 |
|
|
2026
Q1 | $12.4M | Sell |
67,503
-8,876
| -12% | -$1.64M | 0.05% | 215 |
|
|
2025
Q4 | $13.4M | Sell |
76,379
-12,943
| -14% | -$2.11M | 0.06% | 205 |
|
|
2025
Q3 | $12.5M | Buy |
89,322
+3,355
| +4% | +$454K | 0.05% | 203 |
|
|
2025
Q2 | $10.8M | Buy |
85,967
+84,007
| +4,286% | +$10.5M | 0.05% | 207 |
|
|
2025
Q1 | $268K | Buy |
1,960
+619
| +46% | +$88.5K | ﹤0.01% | 1375 |
|
|
2024
Q4 | $205K | Sell |
1,341
-5,533
| -80% | -$933K | ﹤0.01% | 1555 |
|
|
2024
Q3 | $1.33M | Sell |
6,874
-3,274
| -32% | -$685K | 0.01% | 1018 |
|
|
2024
Q2 | $2.35M | Buy |
10,148
+950
| +10% | +$206K | 0.01% | 649 |
|
|
2024
Q1 | $1.98M | Sell |
9,198
-1,168
| -11% | -$274K | 0.01% | 642 |
|
|
2023
Q4 | $2.68M | Buy |
10,366
+4,298
| +71% | +$1.06M | 0.02% | 470 |
|
|
2023
Q3 | $1.56M | Sell |
6,068
-683
| -10% | -$183K | 0.01% | 655 |
|
|
2023
Q2 | $1.92M | Buy |
6,751
+5,401
| +400% | +$1.61M | ﹤0.01% | 661 |
|
|
2023
Q1 | $375K | Sell |
1,350
-1,231
| -48% | -$341K | 0.01% | 566 |
|
|
2022
Q4 | $599K | Sell |
2,581
-318
| -11% | -$89.8K | 0.01% | 394 |
|
|
2022
Q3 | $775K | Sell |
2,899
-64
| -2% | -$13.6K | 0.01% | 407 |
|
|
2022
Q2 | $602K | Sell |
2,963
-607
| -17% | -$124K | 0.01% | 501 |
|
|
2022
Q1 | $752K | Sell |
3,570
-808
| -18% | -$176K | 0.01% | 484 |
|
|
2021
Q4 | $1.05M | Sell |
4,378
-339
| -7% | -$87.2K | 0.01% | 441 |
|
|
2021
Q3 | $1.33M | Buy |
4,717
+1,316
| +39% | +$431K | 0.02% | 313 |
|
|
2021
Q2 | $1.18M | Sell |
3,401
-383
| -10% | -$116K | 0.02% | 313 |
|
|
2021
Q1 | $1.06M | Buy |
3,784
+390
| +11% | +$105K | 0.02% | 286 |
|
|
2020
Q4 | $831K | Sell |
3,394
-926
| -21% | -$239K | 0.01% | 278 |
|
|
2020
Q3 | $1.23M | Buy |
4,320
+385
| +10% | +$107K | 0.02% | 214 |
|
|
2020
Q2 | $1.05M | Buy |
3,935
+1,739
| +79% | +$523K | 0.02% | 203 |
|
|
2020
Q1 | $695K | Buy |
2,196
+736
| +50% | +$223K | 0.02% | 237 |
|
|
2019
Q4 | $433K | Buy |
1,460
+162
| +12% | +$44.9K | 0.01% | 326 |
|
|
2019
Q3 | $302K | Buy |
+1,298
| New | +$302K | 0.01% | 385 |
|
|
2019
Q2 | – | Sell |
-974
| Closed | -$230K | – | 614 |
|
|
2019
Q1 | $230K | Buy |
974
+409
| +72% | +$129K | 0.01% | 343 |
|
|
2018
Q4 | $170K | Buy |
+565
| New | +$180K | 0.01% | 236 |
|
Other funds holding BIIB
Cresset Asset Management's BIIB Position: Q2 2026 in Review
Cresset Asset Management reduced its Biogen (BIIB) stake by 9.3% in Q2 2026, selling an estimated $1.19M and leaving 61,258 shares worth $13.2M. The position accounts for 0.05% of the portfolio, ranked #233.
Cresset Asset Management first reported a position in BIIB in Q4 2018 and has held it in 30 quarters since. The position peaked at $13.4M in Q4 2025. 1,041 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Cresset Asset Management held 61,258 shares of Biogen worth $13.2M as of Q2 2026.
- Cresset Asset Management sold 6,245 Biogen shares in Q2 2026, an estimated $1.19M.
- Biogen made up 0.05% of Cresset Asset Management's portfolio in Q2 2026, its #233 holding.
- Cresset Asset Management first reported a position in Biogen in Q4 2018 and has held it in 30 quarters since.
- Cresset Asset Management's Biogen position peaked at $13.4M in Q4 2025.
- 1,041 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.